Nanoviricides (NNVC) Accounts Payables (2011 - 2026)
Nanoviricides (NNVC) posted Accounts Payables of $134871.0 for Q1 2026, down 43.18% sequentially from $237367.0 in Q4 2025, and down 83.42% YoY from $813477.0 in Q1 2025.
Nanoviricides (NNVC) Accounts Payables (2011 - 2026) Analysis & Trends
Nanoviricides has reported Accounts Payables for 16 years, with the latest figure at $134871.0 in Q1 2026.
- Quarterly Accounts Payables fell 83.42% year-over-year to $134871.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134871.0 (down 83.42% YoY) and the FY2025 annual result came in at $821456.0, up 118.32% from the prior year.
- Accounts Payables retreated to $134871.0 in Q1 2026 per NNVC's latest filing, from $237367.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $821456.0 in Q2 2025 and troughed at $37690.0 in Q3 2022.
- A 5-year average of $357068.1 and a median of $237367.0 in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2026: Accounts Payables surged 906.86% in 2023, then sank 83.42% in 2026.
- Over 5 years, Accounts Payables stood at $39291.0 in 2022, then jumped by 578.69% to $266663.0 in 2023, then decreased by 10.99% to $237367.0 in 2024, then changed by 0.0% to $237367.0 in 2025, then sank by 43.18% to $134871.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $134871.0, $237367.0, and $237367.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 35.57 Mn |
| 10 | Nanoviricides | 29.28 Mn | 26.07 Mn | - | 905,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134,871.00 |
| Dec 31, 2025 | 237,367.00 |
| Sep 30, 2025 | 237,367.00 |
| Jun 30, 2025 | 821,456.00 |
| Mar 31, 2025 | 813,477.00 |
| Dec 31, 2024 | 237,367.00 |
| Sep 30, 2024 | 636,550.00 |
| Jun 30, 2024 | 376,270.00 |
| Mar 31, 2024 | 213,148.00 |
| Dec 31, 2023 | 266,663.00 |
| Sep 30, 2023 | 379,485.00 |
| Jun 30, 2023 | 733,434.00 |
| Mar 31, 2023 | 62,695.00 |
| Dec 31, 2022 | 39,291.00 |
| Sep 30, 2022 | 37,690.00 |
| Jun 30, 2022 | 720,039.00 |
| Mar 31, 2022 | 122,987.00 |
| Dec 31, 2021 | 153,180.00 |
| Sep 30, 2021 | 116,248.00 |
| Jun 30, 2021 | 200,016.00 |